Prothena plummets after amyloidosis failure

Prothena Corp. plc (NASDAQ:PRTA) sank $25.34 (69%) to $11.50 on Monday after it discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001. The company said the humanized mAb targeting amyloid missed the primary and secondary endpoints in the Phase IIb

Read the full 401 word article

How to gain access

Continue reading with a
two-week free trial.